You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Selective adenosine A2A receptor antagonist and monoamine oxidase B (MAO-B) inhibitor (Ki values are 54 and 28200 nM at rat A2A and A1 receptors respectively and Ki ~ 100 nM at MAO-B). Potently protects against quinolinic acid-induced (Cat. No. 0225) neuronal damage and is neuroprotective in the MPTP model of Parkinson's disease.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 330.77. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.25 mM||12.09 mL||60.46 mL||120.93 mL|
|1.25 mM||2.42 mL||12.09 mL||24.19 mL|
|2.5 mM||1.21 mL||6.05 mL||12.09 mL|
|12.5 mM||0.24 mL||1.21 mL||2.42 mL|
References are publications that support the biological activity of the product.
Chen et al (2002) 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions on monoamine oxidase inhibition and A2A receptor antagonism. J.Biol.Chem. 277 36040 PMID: 12130655
Behan and Stone (2002) Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists. Br.J.Pharmacol. 135 1435 PMID: 11906956
Vlok et al (2006) Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorg.Med.Chem. 14 3512 PMID: 16442801
If you know of a relevant reference for 8-(3-Chlorostyryl)caffeine, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 8-(3-Chlorostyryl)caffeine, 8-(3-Chlorostyryl)caffeine supplier, Selective, A2A, antagonists, MAO-B, inhibitors, inhibits, Receptors, adenosines, Monoamine, Oxygenases, Oxidases, CSC, Adenosine, Oxidase, 5-HT-Related, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT3, 3306, Tocris Bioscience
5 Citations for 8-(3-Chlorostyryl)caffeine
Citations are publications that use Tocris products. Selected citations for 8-(3-Chlorostyryl)caffeine include:
Benada et al (2015) Polo-like kinase 1 inhibits DNA damage response during mitosis. Oncotarget 14 219 PMID: 25607646
Li et al (2014) Regulation of photoreceptor gap junction phosphorylation by adenosine in zebrafish retina. Vis Neurosci 31 237 PMID: 24844306
Factor et al (2007) Adenosine regulation of alveolar fluid clearance. Cell Cycle 104 4083 PMID: 17360481
Bao et al (2013) Pannexin 1 channels link chemoattractant receptor signaling to local excitation and global inhibition responses at the front and back of polarized neutrophils. J Biol Chem 288 22650 PMID: 23798685
Kleiner et al (2018) Activator protein-1 contributes to the NaCl-induced expression of VEGF and PlGF in RPE cells. Mol Vis 24 647 PMID: 30310263
Do you know of a great paper that uses 8-(3-Chlorostyryl)caffeine from Tocris? Please let us know.
Reviews for 8-(3-Chlorostyryl)caffeine
There are currently no reviews for this product. Be the first to review 8-(3-Chlorostyryl)caffeine and earn rewards!
Have you used 8-(3-Chlorostyryl)caffeine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.